Compare PKBK & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PKBK | ABEO |
|---|---|---|
| Founded | 1999 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 281.0M |
| IPO Year | N/A | 1980 |
| Metric | PKBK | ABEO |
|---|---|---|
| Price | $25.20 | $5.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 30.0K | ★ 1.6M |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | ★ 21.56 | N/A |
| EPS | ★ 2.83 | 1.29 |
| Revenue | ★ $71,766,000.00 | $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,590.36 |
| P/E Ratio | $8.90 | ★ $4.17 |
| Revenue Growth | ★ 13.64 | N/A |
| 52 Week Low | $16.94 | $3.93 |
| 52 Week High | $25.23 | $7.54 |
| Indicator | PKBK | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 83.02 | 52.04 |
| Support Level | $23.72 | $4.53 |
| Resistance Level | $24.11 | $5.61 |
| Average True Range (ATR) | 0.50 | 0.27 |
| MACD | 0.21 | 0.08 |
| Stochastic Oscillator | 94.55 | 49.30 |
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.